Hemab Therapeutics, a Phase 3-ready biotech developing blood coagulation disorder treatments, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Hemab is a clinical-stage biotechnology company developing antibody-based therapies for inherited bleeding and coagulation disorders. Its lead candidate, sutacimig (HMB-001), finished Phase 2 and is ready for Phase 3 for Glanzmann thrombasthenia and Phase 2 for Factor VII deficiency, while HMB-002 is in Phase 1/2 for Von Willebrand Disease. The company’s programs are focused on prophylactic subcutaneous treatments for rare disorders with limited existing options, and it is also advancing additional preclinical candidates in coagulation-related diseases.
The Cambridge, MA-based company was founded in 2020 and plans to list on the Nasdaq under the symbol COAG. Hemab Therapeutics filed confidentially on February 27, 2026. Goldman Sachs, Jefferies, and Evercore ISI are the joint bookrunners on the deal.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.